NCT07742228 SCENAR Therapy in Chronic Non-specific Neck Pain
| NCT ID | NCT07742228 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hopital Foch |
| Condition | Cervicalgia |
| Study Type | INTERVENTIONAL |
| Enrollment | 76 participants |
| Start Date | 2026-03-11 |
| Primary Completion | 2028-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 76 participants in total. It began in 2026-03-11 with a primary completion date of 2028-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Shifting away from a medication-centered approach is a major public health priority, particularly in chronic pain management, where non-pharmacological therapies are recommended despite barriers such as limited evidence and low prescriber awareness. SCENAR (Self-Controlled Energo-Neuro Adaptive Regulation), an electrotherapy device, lacks robust randomized controlled trial data. A prior study showed effects in both active and placebo groups after a single session, supporting further investigation. This study aims to assess whether repeated SCENAR sessions improve disability, mobility, and pain in patients with chronic neck pain.
Eligibility Criteria
Inclusion Criteria: * Male or female participants aged 18 years or older * Patients with chronic non-specific cervical spine pain, including cervicobrachial neuralgia, persisting for at least 3 months, with no identifiable underlying cause requiring specific treatment. * Patients who attended a pain clinic consultation or were referred to a pain specialist during hospitalization. * Neck Disability Index (NDI) score of at least 30% (≥15 points). * Written informed consent provided prior to study participation. * Patient affiliated to a national health insurance Exclusion Criteria: * Pregnant women * Skin conditions preventing SCENAR use (wounds, recent scars, skin infections) * Initiation or change of analgesic treatment within 15 days prior to inclusion or during the study * Cervical pain related to inflammatory (spondyloarthropathy, rheumatoid arthritis, chondrocalcinosis), traumatic (fractures, dislocations), tumor-related (metastases, myeloma), infectious (spondylodiscitis), or neurological (intramedullary or posterior fossa tumor) causes * Previous SCENAR or ECOMODYN session * Implanted pacemaker or defibrillator * Inability to understand French * Adults under legal protection * Individuals deprived of liberty or under guardianship
Contact & Investigator
Mireille Michel-Cherqui, MD
PRINCIPAL INVESTIGATOR
Hôpital Foch
Frequently Asked Questions
Who can join the NCT07742228 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Cervicalgia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07742228 currently recruiting?
Yes, NCT07742228 is actively recruiting participants. Contact the research team at m.michel-cherqui@hopital-foch.com for enrollment information.
Where is the NCT07742228 trial being conducted?
This trial is being conducted at Suresnes, France.
Who is sponsoring the NCT07742228 clinical trial?
NCT07742228 is sponsored by Hopital Foch. The principal investigator is Mireille Michel-Cherqui, MD at Hôpital Foch. The trial plans to enroll 76 participants.